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(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.)
Editor: Thomas Schwarz-Romond 1st Editorial Decision 30 November 2012
Thank you very much for submitting your paper on the potential role pf pRB as an obesity suppressor for consideration to The EMBO Journal editorial office. I am also grateful for your patience as it took some time to receive two consistent sets of referee comments.
You will recognize that both scientists express some principle interest in your data. However, both remain at this stage unconvinced that sufficient and conclusive support for the proposed mechanism had been provided. Accordingly, both demand more and particularly direct molecular evidence to underline the observed phenotypes of pRB in POMC neurons. Seeing the potential of the study though, and conditioned that you were willing and able to invest the necessary time and resources to overcome their criticisms, we are willing to offer a round of major revisions to address their explicit concerns.
Please do not hesitate to contact me with in case of any questions OR indeed to outline the timeframe for necessary experimental work, respective to request additional time beyond our usual 3 month' deadline (preferably via E-mail).
I hope that the constructive referee comments facilitate efficient proceedings for your study while outlining necessary further experimentation.
Please be reminded that the final decision for potential publication here will critically depend of the content and presentation of the revised study and will involve reassessment by our external referees.
REFEREE REPORTS:
Referee #1:
This paper summarizes set of experiments to argue that pRB, a transcription factor implicated in cancers, plays a physiological role in regulation of POMC neurons. Suppression of pRB activity by phosphorylation or genetic knockdown lead to overeating and such overeating during high fat feeding is suggested to be the cause of pRB phosphorylation by high fat feeding-induced AMPK activity.
Overall, the disclosed data is interesting, but fails to provide a compelling mechanistic explanation regarding how pRB function leads to altered firing of POMC neurons.
Major points:
1) The Introduction is discussing papers and their interpretations that are unproven. For example, the notion that only POMC neurons would be affected by HFD is incorrect and many recent papers addressed that question forcefully and directly, including electrophysiology. Equally ambiguous is the relevance of newly born cells in CNTF's action. The human data discussed from a recent work of Thaler et al should also be toned down. The disclosed images in the paper reveal no discernable differences that would be specific to the hypothalamus.
2) If AMPK is a critical driver of pRB phosphorylation, then the same events should occur during fasting or calorie restriction conditions as well. This needs to be addressed directly.
3) Increase in soma size does not mean degeneration. The quantification of POMC neurons in the study is unacceptable from a scientific point of view. There is no proof that the actual cells are missing. Also, the Fig. 2 panels that depict the differential size of POMC neurons need to be reassembled to convince the reader that we are looking at the same exact areas. 4) Electrophysiology need to be used to support the notion of impaired POMC neuronal function.
Referee #2:
Review of manuscript EMBOJ-2012-83618 "pRb is an obesity suppressor in hypothalamus and high-fat diet inhibits pRb in this Location ª The manuscript from Lu et al explores the role of retinoblastoma (Rb) in the neogenesis, survival and function of key neuronal circuitry involved in the hypothalamic regulation of energy balance. It has been recently shown that obese condition and high fat feeding can severely compromise the proper establishment of neuronal circuitry in the arcuate nucleus of the hypothalamus in which antagonistic neuronal population, namely the orexigenic NPY/AgRP neurons and the POMC neurons positively and negatively regulate feeding and energy expenditure. The authors explore the possibility that mechanism that regulates cell cycle re entry could be important in that process and provide a molecular link between high fat feeding and obesity.
Notably the authors show that high fat feeding indeed results in the phosphorylation of Rb in hypothalamic cells. AMPK agonist AICAR also triggers Rb phosphorylation and activation of E2F target gene de repression. They also explore the identity of the neurons affected by HFD-induce Rb phosphorylation by using mouse genetically ingineered for GFP expression in POMC expressing neurons and NPY/AgRP neurons. They could find that a downstream target of pRb, E2F1 is indeed positively regulated as a result of E2F de repression.
To demonstrate causal role in pRb phosphorylation in the fate of arcaute cells, the authors used pan neuronal and neuron-specific deletion of Rb1.Deletion of Rb1 in POMC expressing cells leads to a progressive loss of POMC neurons and the consequent reduction of -MSH in hypothalamic target structures where POMC neurons project. The authors used several combination of intracerebro ventricular (I.C.V) injection of melanocortin receptor agonist and antagonist to demonstrate to formally demonstrate that the reduction of a-MSH release and binding to post synaptic target cells bearing melanocortin receptor that is associated with POMC specific deletion of Rb1 leads to a decrease in melanocortin tone. Noteworthy, animals lacking Rb1 in POMC neurons display increase naso-anal length, a specific feature of melanocortin signaling deregulation. As expected, animals lacking Rb1 in POMC neurons display increased adiposity, obesity, hyperphagia and glucose intolerance and uncontrolled glycemia. The authors went in showing that POMC-specific deletion of Rb1 compromise POMC neurons survival due to POMC cells re-entry in the cell cycle and eventually death by apoptosis. The authors continue by exploring which of the downstream target of pRb p27 and/or E2F1 is mediating the biological consequence of pRb deletion in POMC neurons. They authors showed that the obesity phenotype was corrected in a genetic background where E2F1 was deleted but not in a genetic context of p27 manipulation, that only corrected the pituitary tumors associated with Rb1 deletion in non-hypothalamic POMC cells. The role of pRb was selective to POMC neurons since Rb1 deletion restricted to AgRP neurons was without consequence on body weight and NPY/AgRP neurons survival.
This study provides described in details a new mechanism that could reveal a potential target for anti-obesity strategy. The study is on overall well conducted and the methodology appropriate. Nevertheless several point needs to be addressed in order to support the main claim of the paper.
Major comments to the authors 1-A stated by the authors POMC expression is not restricted to arcuate POMC neurons but extend to others structures including the NTS and the pituitary. The experiment showing that p27 manipulation prevent tumors to occurs but does not rescue the obesity and the loss of POMC neurons is a strong argument to rule out a potential role for pituitary POMC cells to the obese phenotype, nevertheless an alteration of pituitary POMC neurons even in absence of tumors cannot be ruled out and hence a potential contribution to the obese phenotype. The same applies to deletion of E2F1, in which no evidence is given to specifically address the function of pituitary POMC cells lacking RB1 and E2F. To what extend E2F1 deletion also rescue a possible dysfunction in pituitary POMC cells. The authors to provide additional evidence that arcuate POMC neurons are solely driving the phenotype observed in mice lacking RB1 in POMC cells.
2-Animals were of mixed genetic background of C57Bl6J, 129Sv, and FBV. These backgrounds are known to severely diverge from their ability to develop obesity. The number of animals used in the studies usually varies between 3 to 8. Considering the intrinsic variability in the background the authors should provide information regarding the relative enrichment of each background or, alternatively, consider including more controls in some key experiment. This point especially applies for what seems to be a key experiment presented in Figure S5 where mice lacking RB1 in POMC cells do not developed obesity while being put on E2F1-/-background. Please provide some additional information regarding the pituitary function in these animals, such as histology. In addition, plasma glucose could be measured in these animals in order to evaluate if obesity, but not necessarily diabetes is corrected in POMC-Cre; Rblox/lox; E2F1-/-animals.
Minor comments to the authors 1-The manuscript would beneficiate from editing, since several sentences are overly long and clumsy. Different title could even be considered that would gain in strengths and visibility.
1st Revision -authors' response 08 January 2013
Response Page 1
AUTHORS' RESPONSES TO REFEREES' COMMENTS
1) The Introduction is discussing papers and their interpretations that are unproven. For example, the notion that only POMC neurons would be affected by HFD is incorrect and many recent papers addressed that question forcefully and directly, including electrophysiology. Equally ambiguous is the relevance of newly born cells in CNTF's action. The human data discussed from a recent work of Thaler et al should also be toned down. The disclosed images in the paper reveal no discernable differences that would be specific to the hypothalamus. (Lee et al, Nat. Neurosci. 2012 and Li et al, Nat Cell Biol. 2012) , and pointed out some diametrical discrepancies among these papers. We combined the 5 th and 6 th paragraphs into one and concluded it by pointing out the need for further studies.
We have now performed fasting-refeeding experiments and presented the results in Figure  S1D . After 24 hr fasting, ARC showed positive stain by pRbS608p antibody; 3 hr refeeding reduced the positive stain to baseline background level.
3) Increase in soma size does not mean degeneration. The quantification of POMC neurons in the study is unacceptable from a scientific point of view. There is no proof that the actual cells are missing. Also, the Fig. 2 panels that depict the differential size of POMC neurons need to be re-assembled to convince the reader that we are looking at the same exact areas.
We deleted the words "suggesting neuronal degeneration " at the end of the sentence "…the remaining POMC neurons progressively increased their soma sizes, suggesting neuronal degeneration ( Figure 2AC )." at the end of the 2 nd paragraph in the section "Rb1 is required for POMC neuron maintenance".
We presented four new photos for Figure 2A to show POMC stains of ARC sections at similar positions. For Figure 2B , we used a more informative way of presenting POMC neuron counts in ARC by showing counts on sections at three positions.
At the end of the 2 nd paragraph in "Rb1 is required for POMC neuron maintenance", we cautioned the possibility that POMC neuron cells might still be present but not expressing POMC and therefore would not be detected by the anti-POMC IHC used in this Figure. We then refer the readers to RosaYFP experiments in Figure S3GH .
Response Page 2 4) Electrophysiology need to be used to support the notion of impaired POMC neuronal function.
We collaborated with Dr. Young Hwan Jo, a POMC neuron electrophysiologist at Einstein Diabetes Center. Dr. Jo performed electrophysiology experiments on PomcCre;Rb1 lox/lox ;RosaYFP mice at 4 weeks of age, when the brain is sufficiently large for patchclamp experiment. Rb1 deficient POMC neurons showed cell cycle reentry at 1 week of age, increased apoptosis at 2 weeks, and incurred significant cell number reduction and cell size enlargement at 4 weeks. Dr. Jo picked large YFP positive cells for whole-cell patch-clamp recordings in current-clamp mode. Dr. Jo found that Rb1 deficient POMC neurons did not show spontaneous action potential discharge (Panel A) but responded to depolarizing current injections with action potential discharge (Panel B). This finding suggests that Rb1 deficient POMC neurons' excitability is impaired but not abolished at 4 weeks of age.
At this point, it is extremely difficult to reach an interpretation for this finding and, based on it, to carry the electrophysiology experiments forward. Currently, Rb1 does not have a direct link to the neuron polarization and depolarization machinery. Cell cycle reentry and apoptosis, which are firmly linked to Rb1 function, could affect neuron excitability indirectly. By 4 weeks of age, Pomc-Cre;Rb1 lox/lox mice contained significantly fewer POMC neurons, which could alter synaptic connections to affect neuron excitability. Furthermore, high levels of serum leptin, insulin and glucose present in Pomc-Cre;Rb1 lox/lox mice could affect POMC neuron excitability. Patch clamp experiments with POMC neurons in Pomc-Cre;Rb1 lox/lox mice are also not technically productive due to the presence of significantly fewer POMC neurons by 4 weeks of age.
With these considerations, we included this finding as "unpublished results" with a short discussion when describing Figure S3GH .
Referee #2: Major comments to the authors 1-A stated by the authors POMC expression is not restricted to arcuate POMC neurons but extend to others structures including the NTS and the pituitary. The experiment showing that p27 manipulation prevent tumors to occurs but does not rescue the obesity and the loss of POMC neurons is a strong argument to rule out a potential role for pituitary POMC cells to the obese phenotype, nevertheless an alteration of pituitary POMC neurons even in absence of tumors cannot be ruled out and hence a potential contribution to the obese phenotype. The same applies to deletion of E2F1, in which no evidence is given to specifically address the function of pituitary POMC cells lacking RB1 and E2F. To what extend E2F1 deletion also Response Page 3 rescue a possible dysfunction in pituitary POMC cells. The authors to provide additional evidence that arcuate POMC neurons are solely driving the phenotype observed in mice lacking RB1 in POMC cells.
We have now examined the pituitary of Pomc-Cre;Rb1 lox/lox ;E2f1 -/-mice and found that pituitary IL tumors were delayed in them. At 8 weeks of age, IL showed WT sizes (the new Figure S5F) ; but these mice developed macroscopic pituitary tumors at 6 month of age. Since combined E2f1 deletion also delayed obesity development in the Pomc-Cre;Rb1 lox/lox mice (opposite from p27T187A KI or Skp2Het discussed above), this finding would appear to favor the argument that pituitary tumorigenesis caused obesity. Along this line, we also note that E2f1 KO mice showed low adipocity on Chow feed and resisted obesity on HFD (Fajas et al, Dev. Cell 2002) , indicating caution in the interpretation of the correction of obesity by E2f1 deletion (see the new text at the end of the "Repression of E2F1 is a major function of pRb in POMC neurons" section).
We provided additional evidence that Pomc-Cre deletion of Rb1 in pituitary is not responsible for obesity of the Pomc-Cre;Rb1 lox/lox mice. p27T187 KI completely blocked pituitary tumorigenesis in Pomc-Cre;Rb1 lox/lox mice by inducing melanotroph apoptosis such that the entire IL was almost ablated (Figure S4 ), creating melanotroph deficiency. We have now examined PomcCre;Rb1 lox/lox ;Skp2 +/-mice as shown in the new Figure S4Cabc and GHI. Results from these studies show that Pomc-Cre;Rb1 lox/lox ;Skp2 +/-mice had no pituitary tumors and pituitary IL was of the same size as WT pituitary IL. These mice still showed reduced POMC neurons in ARC, and developed obesity, providing additional confidence that pituitary abnormalities in PomcCre;Rb1 lox/lox mice are not the cause of obesity in them. We also mentioned this issue earlier when we first described the obesity phenotype (Figure 3 ) and the pituitary phenotype ( Figure  S3EF ).
We realize that the ultimate way to prove that "arcuate POMC neurons are solely driving the phenotype observed in mice lacking RB1 in POMC cells" is to delete Rb1 in and only in ARC POMC neurons. Extensive studies of the POMC gene promoter did not identify a promoter fragment that is active only in ARC POMC neurons. We have now edited the text (second paragraph) of the section "Pomc-Cre;Rb1 lox/lox mice develop a hyperphagia-obesity-diabetes syndrome" to make this situation clear to the readers.
We have used seven transgenic lines. KO and KI lines were C57Bl6J-129Sv hybrids, transgenic lines were generated on the FVB strain background and subsequently crossed with C57Bl:129Sv hybrids. Since we did not intentionally select for or against a particular strain background, we believe the three strain backgrounds (C57Bl, 129Sv, and FVB) contributed Response Page 4 equally to our testing mice. We have now made a note of this in Methods-Animals and genotyping.
Our initial studies of pRb phosphorylation in ARC in response to HFD used WT C57Bl6 mice. When we extended the pRb phosphorylation studies to mixed background strains, we observed similar pRb phosphorylation effects consistently. Pituitary tumors, POMC neuron loss, and obesity in Pomc-Cre;Rb1 lox/lox mice and, in contrast, lack of AGRP/NPY neuron defects and lack of obesity in Agrp-Cre;Rb1 loxlox mice are robust phenotypes among littermates and among large numbers of litters. The block of pituitary tumors and the non-correction of POMC neuron defects and obesity by Skp2Het and p27T187A KI are also robust phenotypes. The block of pituitary tumors and correction of POMC neuron defects by E2f1 KO are robust, while the correction of obesity body phenotypes by E2f1 is less robust and subject to complex interpretations as discussed above.
Histological studies of Pomc-Cre;Rb1 lox/lox ;E2f1 -/-pituitaries are now provided in Figure S5F (see also discussions on this in Response to point #1).
We regret we did not perform blood tests for leptin, insulin, or glucose for PomcCre;Rb1 lox/lox ;E2f1 -/-mice and did not collect sera when these mice were sacrificed. We intended and are proposing to focus on the effects of combined E2f1 deletion on POMC neurons, since the interpretation of body phenotype correction is complex, as discussed above in Response to point #1.
We have now more carefully edited the language style of this manuscript, focusing on deleting unnecessary words and phrases. For one example, we changed "As an example, the granular zone of dentate gyrus (DG) contains densely packed neurons as shown by NeuN stain; but none of these neurons showed positive co-stain with pRbS608p in the same HFD brain sections ( Figure S1A )" to "As an example, the granular zone of dentate gyrus (DG) contains densely packed neurons as shown by NeuN stain; but none of them showed positive co-stain with pRbS608p in the same HFD brain sections ( Figure S1A )", near the end of the first Results section.
We have not been able to generate a different title that is better than the original (and current) title. We are however receptive to suggestions from reviewers and editors for alternative titles to gain in strengths and visibility for our work.
